4.5 Review

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 15, Issue 5, Pages 557-577

Publisher

INFORMA HEALTHCARE
DOI: 10.1517/14728222.2011.560837

Keywords

-

Funding

  1. NIDA, NIH, DHHS
  2. Japan Society for the Promotion of Sciences (JSPS)

Ask authors/readers for more resources

Areas covered: Recent evidence that has shed light on sigma-1 receptor ligands, which may serve as a new class of antidepressants or neuroprotective agents. Sigma-1 receptors are novel ligand-operated molecular chaperones regulating signal transduction, ER stress, cellular redox, cellular survival and synaptogenesis. Selective sigma-1 receptor ligands exert rapid antidepressant-like, anxiolytic, antinociceptive and robust neuroprotective actions in preclinical studies. Recent studies that suggest that reactive oxygen species might play a role as signal integrators downstream of Sig-1Rs are also covered. Expert opinion: The advances in sigma receptor research in the last decade have begun to elucidate the intracellular signal cascades upstream and downstream of sigma-1 receptors. The novel ligand-operated properties of the sigma-1 receptor chaperone may enable interventions by which stress-related cellular systems can be pharmacologically controlled.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available